### Edgar Filing: NEKTAR THERAPEUTICS - Form 3

#### **NEKTAR THERAPEUTICS**

Form 3

March 23, 2005

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 

3235-0104

0.5

Number: January 31,

**OMB APPROVAL** 

Expires: 2005

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Estimated average burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Krivulka Joseph J

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

03/21/2005

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

NEKTAR THERAPEUTICS [NKTR]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD

(Street)

(Check all applicable)

(give title below) (specify below)

10% Owner \_X\_ Director Officer Other

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One Reporting Person

SAN CARLOS. CAÂ 94070

(City) 1. Title of Security

(Instr. 4)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership 4. Nature of Indirect Beneficial

Ownership (Instr. 5)

Form: Direct (D) or Indirect (I)

(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

**Expiration Date** (Month/Day/Year)

2. Date Exercisable and

3. Title and Amount of Securities Underlying **Derivative Security** 

4 Conversion or Exercise

5. Ownership Form of Derivative

Security:

Direct (D)

6. Nature of Indirect Beneficial Ownership

(Instr. 4)

Date **Expiration Title** Exercisable Date

Amount or Number of

Price of Derivative Security

(Instr. 5)

1

#### Edgar Filing: NEKTAR THERAPEUTICS - Form 3

Shares or Indirect (I)

(Instr. 5)

## **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Krivulka Joseph J C/O NEKTAR THERAPEUTICS 150 INDUSTRIAL ROAD SAN CARLOS, CAÂ 94070

 $\hat{A} X \qquad \hat{A} \qquad \hat{A} \qquad \hat{A}$ 

### **Signatures**

/s/ Joseph J Krivulka 03/23/2005

\*\*Signature of Date
Reporting Person

# **Explanation of Responses:**

No securities are beneficially owned

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2